Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
Immune checkpoint inhibitors and antiangiogenic agents have shown some activity in patients with late-stage gastric cancer. Here the authors report the results of a phase II trial of neoadjuvant anti-PD1 (camrelizumab), antiangiogenic agent (apatinib), and chemotherapy (S-1 ± Oxaliplatin) in stage T...
Full description
Bibliographic Details
Main Authors: |
Song Li,
Wenbin Yu,
Fei Xie,
Haitao Luo,
Zhimin Liu,
Weiwei Lv,
Duanbo Shi,
Dexin Yu,
Peng Gao,
Cheng Chen,
Meng Wei,
Wenhao Zhou,
Jiaqian Wang,
Zhikun Zhao,
Xin Dai,
Qian Xu,
Xue Zhang,
Miao Huang,
Kai Huang,
Jian Wang,
Jisheng Li,
Lei Sheng,
Lian Liu |
Format: | Article
|
Language: | English |
Published: |
Nature Portfolio
2023-01-01
|
Series: | Nature Communications
|
Online Access: | https://doi.org/10.1038/s41467-022-35431-x
|